156 related articles for article (PubMed ID: 2129648)
1. In-vivo anti-reflux and raft properties of alginates.
Lambert JR; Korman MG; Nicholson L; Chan JG
Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
[TBL] [Abstract][Full Text] [Related]
2. A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension.
Washington N; Greaves JL; Iftikhar SY
Aliment Pharmacol Ther; 1992 Oct; 6(5):579-88. PubMed ID: 1420749
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
Ward AE
Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
[No Abstract] [Full Text] [Related]
4. Algicon in the management of gastro-oesophageal reflux.
Lambert JR; Korman MG; Nicholson L
Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
[No Abstract] [Full Text] [Related]
5. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
6. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
7. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
8. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
9. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
13. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children.
Buts JP; Barudi C; Otte JB
Eur J Pediatr; 1987 Mar; 146(2):156-8. PubMed ID: 3032640
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
Guerre J; Neuman M; Bouchet J
Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
[No Abstract] [Full Text] [Related]
15. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
[TBL] [Abstract][Full Text] [Related]
16. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux.
Greally P; Hampton FJ; MacFadyen UM; Simpson H
Arch Dis Child; 1992 May; 67(5):618-21. PubMed ID: 1599300
[TBL] [Abstract][Full Text] [Related]
17. A comparison between cisapride and Gaviscon with Carobel in the treatment of gastro-oesophageal reflux in infancy.
Greally P; Hampton FJ; MacFadyen UM; Simpson H
Ir Med J; 1992; 85(4 Suppl):14. PubMed ID: 1490841
[No Abstract] [Full Text] [Related]
18. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
[TBL] [Abstract][Full Text] [Related]
19. [Can acid pocket-targeting alginate-antacid (Gaviscon Double Action) relieve upper gastrointestinal symptoms in gastro-oesophageal reflux disease?].
Kim SE; Park MI
Korean J Gastroenterol; 2014 Jun; 63(6):386-8. PubMed ID: 25097964
[No Abstract] [Full Text] [Related]
20. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy.
Lang GD; Dougall A
Br J Clin Pract Suppl; 1989 Feb; 66():48-51; discussion 61-4. PubMed ID: 2556175
[No Abstract] [Full Text] [Related]
[Next] [New Search]
